ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Aptamers link Archemix, Elan

July 24, 2006 | APPEARED IN VOLUME 84, ISSUE 30

Archemix and Elan have joined forces to discover and develop aptamers, single-stranded nucleic acids whose binding behavior is similar to that of antibodies, for the treatment of autoimmune disease. Archemix snares a $7 million up-front payment from Elan and could receive more than $350 million in milestones and royalties. The companies will target IL-23, a cytokine that is a mediator in chronic autoimmune inflammatory diseases such as multiple sclerosis, Crohn's disease, psoriasis, and rheumatoid arthritis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment